Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03778931 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
A Phase 3 study, sponsored by Stemline Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 478
- Enrollment target
NCT03778931 is a Phase 3 study that has completed, run by Stemline Therapeutics. The registered enrollment target is 478 participants.
The verdict
NCT03778931, a Phase 3 study, has completed, sponsored by Stemline Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 478 participants
- Enrollment target
Study Summary
This Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6 inhibitor in combination with fulvestrant or an aromatase inhibitor (AI).
Interventions
- DRUG Standard of Care
- DRUG Elacestrant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 478 participants |
| Start Date | 2019-05-10 |
| Est. Completion | 2024-08-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03778931
The ClinicalTrials.gov registry entry for NCT03778931 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 478 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stemline Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT03778931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03778931 about?
NCT03778931 is a clinical study titled "Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer". This Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6 inhibitor in combination...
What is the current status of trial NCT03778931?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 478 participants. The study started on 2019-05-10. Estimated completion is 2024-08-22.
What interventions are being tested in trial NCT03778931?
The interventions under investigation include: Standard of Care (DRUG), Elacestrant (DRUG).
Who is sponsoring clinical trial NCT03778931?
This trial is sponsored by Stemline Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.